GHB and synthetic cathinones: Clinical effects and potential consequences

Drug Testing and Analysis

Volumn 3, Issue 9, 2011, Pages 552-559

  Karila, Laurent ^a,b,c   Reynaud, Michel ^a,b,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c DIF   (France)

^d Universite Paris Sud   (France)

Author keywords

Club drugs; Designer drugs; Flephedrone; GHB; MDAI; MDVP; Mephedrone; Methylone; Party drugs; Synthetic cathinones

Indexed keywords

PARKS;

CATHINONE; CLUB DRUG; DESIGNER DRUGS; FLEPHEDRONE; GHB; MDAI; MDVP; MEPHEDRONE; METHYLONE; PARTY DRUG; SYNTHETIC CATHINONE;

WEBSITES;

1,4 BUTANEDIOL; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4' METHYLMETHCATHINONE; 5,6 METHYLENEDIOXY 2 AMINOINDANE; BENZODIAZEPINE DERIVATIVE; BUPHEDRONE; BUTYLONE; CATHINONE; DESIGNER DRUG; DOPAMINE; FLEPHEDRONE; GAMMA BUTYROLACTONE; METHEDRONE; METHYLENEDIOXYPYROVALERONE; METHYLONE; OXYBATE SODIUM; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ALCOHOL WITHDRAWAL; ALERTNESS; ANOREXIA; ANTEROGRADE AMNESIA; ANXIETY; BEHAVIOR DISORDER; BRUXISM; CATAPLEXY; COGNITIVE DEFECT; COMA; COORDINATION DISORDER; DELUSION; DEPERSONALIZATION; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DEPENDENCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INFORMATION; DRUG INTOXICATION; DRUG METABOLISM; DRUG MISUSE; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG URINE LEVEL; DRUG USE; DYSPHORIA; EMBASE; EMPATHY; EUPHORIA; FIBROMYALGIA; GASTROINTESTINAL IRRITATION; GOVERNMENT; HALLUCINATION; HUMAN; HYPERTENSION; HYPERTHERMIA; INSOMNIA; INTERNET; LEGAL ASPECT; MEDLINE; MYDRIASIS; NARCOLEPSY; NAUSEA; NYSTAGMUS; PARANOIA; PARKINSON DISEASE; PLEASURE; PRIORITY JOURNAL; PROTEIN BINDING; PSYCHOSIS; PSYCINFO; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLURRED SPEECH; SUICIDAL IDEATION; SWEATING; TACHYCARDIA; TRISMUS; UNCONSCIOUSNESS; VOMITING; WITHDRAWAL SYNDROME;

EID: 80053422684     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.210     Document Type: Review

References (98)

1. J. C. Maxwell, Party drugs: properties, prevalence, patterns, and problems, Subst. Use Misuse 2005, 40, 1203.
2. What are club drugs? Here's a quick look, AIDS Alert 2002, 17, 123.
3. NIDA, Pharmacology and toxicology of amphetamine and related designer drugs. NIDA, Res. Monogr. 1989, 94, 358.
4. A. R Winstock, J. D. Ramsey, Legal highs and the challenges for policy makers, Addiction 2010, 105, 1685.
5. J. Hillebrand, D. Olszewski, R. Sedefov, Legal highs on the Internet, Subst. Use Misuse 2010, 45, 330.
6. J. Goss, Designer drugs. Assess & manage patients intoxicated with ecstasy, GHB or rohypnol-the three most commonly abused designer drugs, J.E.M.S. 2001, 26, 84.
7. C. Haas, L. Karila, W. Lowenstein, Cocaine and crack addiction: a growing public health problem, B. Acad. Nat. Med. Paris 2009, 193, 947.
8. D. Velea, M. Hautefeuille, G. Vazeille, C. Lantran-Davoux, New synthesis empathogenic agents, Encephale 1999, 25, 508.
9. T. van Havere, W. Vanderplasschen, E. Broekaert, I. de Bourdeaudhui, The influence of age and gender on party drug use among young adults attending dance events, clubs, and rock festivals in Belgium, Subst. Use Misuse 2009, 44, 1899.
10. G. Quintero, Rx for a party: a qualitative analysis of recreational pharmaceutical use in a collegiate setting, J. Am. Coll. Health 2009, 58, 64.
11. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), EMCDDA and Europol step up information collection on mephedrone (2010). Available at: .
12. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), EMCDDA-Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA, EMCDDA, Lisbon, 2010.
13. M. R. Meyer, H. H. Maurer, Metabolism of designer drugs of abuse: an updated review, Curr. Drug Metab. 2010, 11, 468.
14. EMCDDA, European Monitoring Center for Drugs and Drug Abuse: Annual report 2006: The state of the drug problem in Europe. Available at: [2009].
15. A. L. Jones, Legal 'highs' available through the Internet-implications and solutions? Q. J. Med. 2010, 103, 535.
16. A. Benyamina, L. Bonhomme-Faivre, V. Picard, A. Sabbagh, D. Richard, L. Blecha, H. Rahioui, L. Karila, M. Lukasiewicz, R. Farinotti, Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence, Pro. Neuro-Psychoph. 2009, 33, 1270.
17. P. G. Miller, A. L. Sonderlund, Using the internet to research hidden populations of illicit drug users: a review, Addiction. 2010, 105, 1557.
18. H. Laborit, J. M. Jouany, J. Gérard, F. Fabiani, Generalities concerning the experimental study and clinical use of gamma hydroxybutyrate of Na, Agressologie 1960, 1, 397.
19. S. P. Bessman, W. N. Fishbein, Gamma-hydroxybutyrate, a normal brain metabolite, Nature 1963, 200, 1207.
20. M. Maitre, J. P. Humbert, V. Kemmel, D. Aunis, C. Andriamampandry, A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse, Med. Sci. (Paris) 2005, 21, 284.
21. M. Maitre, The gamma-hydroxybutyrate signalling system in brain: organization and functional implications, Prog. Neurobiol. 1997, 51, 337.
22. M. Maitre, V. Hechler, P. Vayer, S. Gobaille, C. D. Cash, M. Schmitt, J. J. Bourguignon, A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant propertiesm, J. Pharmacol. Exp. Ther. 1990, 255, 657.
23. J. Takahara, S. Yunoki, W. Yakushiji, J. Yamauchi, Y. Yamane, Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans, J. Clin. Endocr. Metab. 1977, 44, 1014.
24. R. Wise, Brain reward circuitry: insights from unsensed incentives, Neuron 2002, 36, 229.
25. G. Koob, M. Le Moal, Drug addiction, dysregulation of reward, and allostasis, Neuropsychopharmacol. 2001, 24, 97.
26. E. Nestler, Molecular neurobiology of addiction, Am. J. Addict. 2001, 10, 201.
27. J. Cami, M. Farre, Drug addiction, New Engl. J. Med. 2003, 349, 975.
28. M. Shannon, L. S. Quang, Gamma-hydroxybutyrate, gamma-butyrolactone, and 1, 4-butanediol: a case report and review of the literature, Pediatr. Emerg. Care. 2000, 16, 435.
29. L. Karila, J. Novarin, B. Megarbane, O. Cottencin, S. Dally, W. Lowenstein, M. Reynaud, Gamma-hydroxybutyric acid (GHB): more than a date rape drug, a potentially addictive drug, Presse. Med. 2009, 38, 1526.
30. L. Slaughter, Involvement of drugs in sexual assault, J. Reprod. Med. 2000, 45, 425.
31. K. M. Smith, Drugs used in acquaintance rape, J. Am. Pharm. Assoc. (Wash. DC) 1999, 39, 519, quiz 581.
32. K. M. Smith, L. L. Larive, F. Romanelli, Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate, Am. J. Health-Syst. Ph. 2002, 59, 1067.
33. M. E. Stillwell, Drug-facilitated sexual assault involving gamma-hydroxybutyric acid, J. Forensic Sci. 2002, 47, 1133.
34. H. R. Sum.nall, K. Woolfall, S. Edwards, J. C. Cole, C. M. Beynon, Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB), Drug Alcohol Depen. 2008, 92, 286.
35. M. Varela, S. Nogue, M. Oros, O. Miro, Gamma hydroxybutirate use for sexual assault, Emerg. Med. 2004, 21, 255.
36. G. C. Britt, E. F. McCance-Katz, A brief overview of the clinical pharmacology of 'club drugs', Subst. Use Misuse 2005, 40, 1189.
37. EMCDDA, EMCDDA Thematic Papers-GHB and its precursor GBL: an emerging trend case study, EMCDDA, Lisbon, 2008.
38. M. Gandilhon, A. Cadet.-Tairou, A. Toufik, I. Evrard, Septième rapport national du dispositif TREND, Tendances 2006, 52.
39. A. Cadet.-Tairou, M. Gandilhon, A. Toufik, I. Evrard, Huitième rapport national du dispositif TREND, Tendances 2008, 58.
40. M. Atha, S. Davis, Gamma hydroxy butyrate usage, effects and UK prices: Results from 1999-2002 IDMU surveys. Available at: [2003].
41. E. Kaufmann, A. Alt, Determination of GHB in urine and serum by LC/MS using a simple one-step derivative, Forensic Sci. Int. 2007, 168, 133.
42. S. Y. Kim, J. C. Barker, I. B. Anderson, J. E. Dyer, G. Earnest, P. D. Blanc, Systematic assessment of gamma hydroxybutyrate (GHB) effects during and after acute intoxication, Am. J. Addict. 2008, 17, 312.
43. Q. Bodson, R. Denooz, P. Serpe, C. Charlier, Gamma-hydroxybutyric acid (GHB) measurement by GC-MS in blood, urine and gastric contents, following an acute intoxication in Belgium, Acta. Clin. Belg. 2008, 63, 200.
44. A. Gonzalez, D. J. Nutt, Gamma hydroxy butyrate abuse and dependency, J Psychopharmacol. 2005, 19, 195.
45. D. Ward, J. Morgenthaler, S. Fowkes, GHB-the natural mood enhancer, Smart Publications: Petaluma, 1998.
46. A. Oliveto, W. B. Gentry, R. Pruzinsky, K. Gonsai, T. R. Kosten, B. Martell, J. Poling, Behavioral effects of gamma-hydroxybutyrate in humans, Behav. Pharmacol. 2010, 21, 332.
47. M. S. Okun, L. A. Boothby, R. B. Bartfield, P. L. Doering, GHB: an important pharmacologic and clinical update, J. Pharm. Pharm. Sci. 2001, 4, 167.
48. P. A. Bialer, Designer drugs in the general hospital, Psychiat. Clin. N. Am. 2002, 25, 231.
49. G. P. Galloway, S. L. Frederick, F. E. Staggers Jr., M. Gonzales, S. A. Stalcup, D. E. Smith, Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence, Addiction 1997, 92, 89.
50. P. Kintz, M. Villain, A. L. Pelissier, V. Cirimele, G. Leonetti, Unusually high concentrations in a fatal GHB case, J. Anal. Toxicol. 2005, 29, 582.
51. S. Mazarr-Proo, S. Kerrigan, Distribution of GHB in tissues and fluids following a fatal overdose, J. Anal. Toxicol. 2005, 29, 398.
52. J. C. Barker, S. L. Harris, J. E. Dyer, Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study, J. Psychoactive Drugs 2007, 39, 115.
53. J. C. Barker, H. Karsoho, Hazardous use of gamma hydroxybutyrate: driving under the influence, Subst. Use Misuse 2008, 43, 1507.
54. S. Y. Kim, I. B. Anderson, J. E. Dyer, J. C. Barker, P. D. Blanc, High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users, Am. J. Drug Alcohol Ab. 2007, 33, 429.
55. T. Antoniou, A. L. Tseng, Interactions between recreational drugs and antiretroviral agents, Ann. Pharmacother 2002, 36, 1598.
56. A. F. Tarabar, L. S. Nelson, The gamma-hydroxybutyrate withdrawal syndrome, Toxicol. Rev. 2004, 23, 45.
57. M. S. van Noorden, L. C. van Dongen, F. G. Zitman, T. A. Vergouwen, Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known, Gen. Hosp. Psychiat. 2009, 31, 394.
58. A. B. Schneir, B. T. Ly, R. F. Clark, A case of withdrawal from the GHB precursors gamma-butyrolactone and 1, 4-butanediol, J. Emerg. Med. 2001, 21, 31.
59. M. McDonough, N. Kennedy, A. Glasper, J. Bearn, Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review, Drug Alcohol Depen. 2004, 75, 3.
60. I. J. Bosman, K. J. Lusthof, Forensic cases involving the use of GHB in the Netherlands, Forensic Sci. Int. 2003, 133, 17.
61. D. G. Caldicott, F. Y. Chow, B. J. Burns, P. D. Felgate, R. W. Byard, Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia, Med. J. Australia 2004, 181, 310.
62. C. Jones, Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity, J. Clin. Forensic Med. 2001, 8, 74.
63. R. Herbrand, P. Greminger, G. Schurter, W. Pletscher, H. Kupferschmidt, Sudden coma in a 20-year-old man, Praxis 2000, 89, 1326.
64. J. M. Wojtowicz, M. C. Yarema, P. M. Wax, Withdrawal from gamma-hydroxybutyrate, 1, 4-butanediol and gamma-butyrolactone: a case report and systematic review, C.J.E.M. 2008, 10, 69.
65. D. M. Robinson, G. M. Keating, Sodium oxybate: a review of its use in the management of narcolepsy, C.N.S. Drugs 2007, 21, 337.
66. Y. Wang, T. Swick, L. Carter, M. Thorpy, N. Benowitz, Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem) : abuse, misuse, dependence and diversion, J. Clin. Sleep Med. 2009, 5, 365.
67. P. Griffiths, D. Lopez, R. Sedefov, A. Gallegos, B. Hughes, A. Noor, L. Royuela, Khat use and monitoring drug use in Europe: The current situation and issues for the future, J. Ethnopharmacol. 2010.
68. S. Gibbons, M. Zloh, An analysis of the 'legal high' mephedrone, Bioorg. Med. Chem. Lett. 2010, 20, 4135.
69. Drugscope. Available at: [2009].
70. D. M. Wood, S. L. Greene, P. I. Dargan, Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone, Emerg. Med. J. 2010.
71. D. M. Wood, S. Davies, M. Puchnarewicz, J. Button, R. Archer, H. Ovaska, J. Ramsey, T. Lee, D. W. Holt, P. I. Dargan, Recreational Use of Mephedrone (4-Methylmethcathinone, 4-MMC) with Associated Sympathomimetic Toxicity, J. Med. Toxicol. 2010, 6, 327.
72. E. Sammler, P. Foley, G. Lauder, S. Wilson, A. Goudie, J. O'Riordan, A harmless high? Lancet 2010, 376, 742.
73. Erowid. Available at: [2010].
74. A. J. Dickson, S. P. Vorce, B. Levine, M. R. Past, Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin, J. Anal. Toxicol. 2010, 34, 162.
75. N. V. Cozzi, M. K. Sievert, A. T. Shulgin, P. Jacob 3rd, A. E. Ruoho, Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines, Eur. J. Pharmacol. 1999, 381, 63.
76. T. Dal Cason, R. Young, R. Glennon, Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs, Pharmacol. Biochem. Be. 1997, 58, 1109.
77. H. T. Kamata, N. Shima, K. Zaitsu, T. Kamata, A. Miki, M. Nishikawa, M. Katagi, H. Tsuchihashi, Metabolism of the recently encountered designer drug, methylone, in humans and rats, Xenobiotica 2006, 36, 709.
78. Erowid. Available at: [July 2010].
79. M. R. Meyer, J. Wilhelm, F. T. Peters, H. H. Maurer, Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry, Anal. Bioanal. Chem. 2010, 397, 1225.
80. E. Shimizu, H. Watanabe, T. Kojima, H. Hagiwara, M. Fujisaki, R. Miyatake, K. Hashimoto, M. Iyo, Combined intoxication with methylone and 5-MeO-MIPT, Prog. Neuro-Psychoph. 2007, 31, 288.
81. M. G. Bossong, J. P. Van Dijk, R. J. Niesink, Methylone and mCPP, two new drugs of abuse? Addict. Biol. 2005, 10, 321.
82. J. G. van Amsterdam, W. Best, A. Opperhuizen, F. A. de Wolff, Evaluation of a procedure to assess the adverse effects of illicit drugs, Regul. Toxicol. Pharm. 2004, 39, 1.
83. Two die of legal drug overdose. The Local, Sweden. Available at: [14 October, 2009].
84. R. P. Archer, Fluoromethcathinone, a new substance of abuse, Forensic Sci. Int. 2009, 185, 10.
85. L. Aerts, M. Mallaret, H. Rigter, N-methyl-1-(1, 3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks, Addict. Biol. 2000, 5, 269.
86. R. Oberlender, D. E. Nichols, (+)-N-methyl-1-(1, 3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3, 4-methylenedioxy-methamphetamine-like behavioral activity, J. Pharmacol. Exp. Ther. 1990, 255, 1098.
87. D. Nichols, Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens, J. Psychoactive Drugs 1986, 18, 305.
88. N. Carter, G. Rutty, C. Milroy, A. Forrest, Deaths associated with MBDB misuse. Int. J. Legal Med. 2000, 113, 168.
89. Erowid. Available at: [July 2010].
90. F. Westphal, T. Junge, P. Rosner, F. Sonnichsen, F. Schuster, Mass and NMR spectroscopic characterization of 3, 4-methylenedioxypyrovalerone: A designer drug with a-pyrrolidinophenone structure, Forensic Sci. Int. 2009, 190, 1.
91. Erowid. Available at: [July 2010].
92. P. Deniker, H. Loo, H. Cuche, J. Roux, Abuse of pyrovalerone in drug addicts, Ann. Med. Psychol. (Paris) 1975, 2, 745.
93. R. Oberlender, D. E. Nichols, Structural variation and (+)-amphetamine-like discriminative stimulus properties, Pharmacol. Biochem. Be. 1991, 38, 581.
94. M. P. Johnson, X. M. Huang, D. E. Nichols, Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3, 4-methylenedioxymethamphetamine (MDMA) analogue, Pharmacol. Biochem. Be. 1991, 40, 915.
95. A. Shaw, Danger drug meow meow's successor MDAI could flood Britain. Available at: [2010].
96. Erowid. Available at: [July 2010].
97. R. H. Schwartz, R. Milteer, M. A. LeBeau, Drug-facilitated sexual assault ('date rape'), South. Med. J. 2000, 93, 558.
98. D. Gustavsson, C. Escher, Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance, Lakartidningen 2009, 106, 2769.